Diabetes

Explore the complexities of Diabetes research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against Diabetes with flcube.com.

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms
CompanyDeals

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms

Bio-Link Capital announced the completion of a strategic investment in TYK Medicines (HKG: 2410), a macromolecule innovative drug company focused on the development of next‑generation antibody therapeutics, including bispecific antibodies,…

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts

CompanyDrug

Sihuan Pharmaceutical Secures NMPA Approval for First Biosimilars of Novo Nordisk’s Diabetes Drugs

CompanyDeals

JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies

CompanyDrug

Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar

CompanyDrug

Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China

CompanyDrug

Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China

CompanyDrug

Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals

Policy / Regulatory

China Unveils Comprehensive 2030 Plan to Combat Diabetes

Show More